Perampanel Vivanta: Uses, Dosage & Side Effects
A once-daily oral selective non-competitive AMPA glutamate receptor antagonist used as adjunctive therapy for focal-onset and primary generalised tonic-clonic seizures in epilepsy
Perampanel Vivanta is a prescription oral antiepileptic medicine containing the active ingredient perampanel, a first-in-class selective non-competitive antagonist of the AMPA glutamate receptor on post-synaptic neurons. It is approved as adjunctive (add-on) therapy for the treatment of focal-onset seizures with or without focal to bilateral tonic-clonic seizures in adults and children aged 4 years and older, and for primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 7 years and older. Perampanel has a long elimination half-life of approximately 105 hours, allowing convenient once-daily administration at bedtime. Treatment is typically initiated at 2 mg daily with gradual upward titration. Because perampanel can cause dose-related neurological and psychiatric adverse effects, including serious behavioural changes, careful patient selection, slow titration, and regular monitoring are essential.
Quick Facts: Perampanel Vivanta
Key Takeaways
- Perampanel Vivanta is a once-daily oral AMPA receptor antagonist used as adjunctive therapy for focal-onset seizures (in patients aged 4 years and older) and primary generalised tonic-clonic seizures (in patients aged 7 years and older) when existing antiepileptic treatment is insufficient.
- Treatment is initiated at 2 mg once daily at bedtime and titrated slowly (typically by 2 mg every 1–2 weeks) to a usual maintenance dose of 4–12 mg daily, based on clinical response and tolerability.
- The most frequent adverse effects are dose-dependent dizziness and somnolence; serious psychiatric and behavioural reactions, including aggression and hostility, require close monitoring and prompt dose adjustment if they occur.
- Perampanel should always be taken at bedtime, swallowed whole with water, and can be taken with or without food; alcohol should be avoided or strictly limited as it markedly worsens mood and psychomotor adverse effects.
- Strong CYP3A4 inducers (such as carbamazepine, phenytoin, and oxcarbazepine) significantly lower perampanel plasma concentrations, while high-dose perampanel (12 mg) can reduce the effectiveness of levonorgestrel-containing hormonal contraceptives.
What Is Perampanel Vivanta and What Is It Used For?
Perampanel Vivanta is a generic formulation of perampanel, a first-in-class antiepileptic drug (AED). Perampanel was originally developed by Eisai and first approved in the European Union in July 2012 and by the U.S. Food and Drug Administration (FDA) in October 2012 under the brand name Fycompa. Since the expiry of market exclusivity, generic formulations such as Perampanel Vivanta have become available, offering equivalent therapeutic efficacy and improved patient access. Each Perampanel Vivanta 2 mg film-coated tablet contains 2 mg of the active substance perampanel, an orally active small molecule with high oral bioavailability and a characteristically long elimination half-life of approximately 105 hours.
Epilepsy is a chronic neurological disorder characterised by a persistent predisposition to generate epileptic seizures. According to the World Health Organization, epilepsy affects approximately 50 million people worldwide, making it one of the most common serious neurological conditions. Despite the availability of more than 30 approved antiepileptic drugs, roughly one third of people with epilepsy do not achieve satisfactory seizure control with their current treatment regimen. This unmet clinical need has driven the development of novel agents such as perampanel that target previously unexploited mechanisms of seizure generation.
Seizures result from abnormal, excessive, and synchronous neuronal firing in the brain. A key driver of this hyperexcitability is excessive activation of glutamate receptors, in particular the fast-acting ionotropic AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors. Glutamate is the principal excitatory neurotransmitter in the central nervous system, and AMPA receptors mediate the initial phase of post-synaptic depolarisation at glutamatergic synapses. By selectively dampening AMPA-mediated excitation, perampanel reduces the propagation of epileptiform activity without broadly suppressing all neuronal signalling.
Perampanel is indicated for the following conditions in epilepsy:
- Adjunctive treatment of focal-onset seizures: Perampanel is approved as add-on therapy for focal-onset seizures (previously known as partial-onset seizures), with or without focal to bilateral tonic-clonic seizures (secondarily generalised tonic-clonic seizures), in adult and paediatric patients from 4 years of age. Focal-onset seizures begin in one area of the brain and may or may not spread to involve both hemispheres. The pivotal registration trials (Studies 304, 305, and 306) enrolled more than 1,400 adult and adolescent patients with uncontrolled focal-onset seizures receiving 1–3 background AEDs and demonstrated statistically significant reductions in seizure frequency with perampanel 4 mg, 8 mg, and 12 mg compared with placebo.
- Adjunctive treatment of primary generalised tonic-clonic seizures: Perampanel is approved as add-on therapy for primary generalised tonic-clonic (PGTC) seizures in adult and paediatric patients from 7 years of age with idiopathic generalised epilepsy. PGTC seizures begin with simultaneous involvement of both cerebral hemispheres from the outset and represent a particularly disabling seizure type associated with increased injury risk and sudden unexpected death in epilepsy (SUDEP). The pivotal Study 332 randomised 164 patients to perampanel 8 mg or placebo and demonstrated a significant reduction in PGTC seizure frequency with perampanel.
Perampanel's distinctive mechanism of action sets it apart from other antiepileptic drugs. Unlike traditional AEDs that primarily modulate voltage-gated sodium channels (phenytoin, carbamazepine, lamotrigine, lacosamide), enhance GABAergic inhibition (benzodiazepines, phenobarbital, valproate), or modulate synaptic vesicle proteins (levetiracetam, brivaracetam), perampanel directly targets AMPA-mediated glutamatergic excitation. This complementary mode of action makes perampanel a rational choice for adjunctive use in patients whose seizures remain uncontrolled on agents with other mechanisms.
Clinical experience since market introduction has established perampanel as a useful option in drug-resistant epilepsy. Real-world observational studies conducted across Europe, Asia, and North America have broadly confirmed the efficacy observed in the randomised trials, with 30–50% of patients achieving a clinically meaningful (≥50%) reduction in seizure frequency during long-term follow-up. Perampanel has also shown efficacy in several other seizure types and epilepsy syndromes studied in open-label extensions and post-marketing cohorts, including juvenile myoclonic epilepsy, Lennox-Gastaut syndrome, and certain progressive myoclonic epilepsies, although these uses may be considered off-label depending on regional approvals.
Adjunctive (add-on) therapy means perampanel is added to an existing antiepileptic drug regimen rather than used alone. This approach is common in refractory epilepsy, where single-agent treatment has failed to adequately control seizures. By combining AEDs with different mechanisms of action, clinicians aim to achieve better seizure control while minimising any single drug's dose-related adverse effects. Perampanel's unique AMPA antagonist mechanism complements the more common sodium-channel, GABAergic, and SV2A-targeting actions of other AEDs.
What Should You Know Before Taking Perampanel Vivanta?
Contraindications
Perampanel Vivanta must not be used in patients with known hypersensitivity to perampanel or to any of the excipients contained in the tablet formulation. Although hypersensitivity reactions are uncommon, they can include skin rash, urticaria, facial and laryngeal oedema, and in rare cases drug reaction with eosinophilia and systemic symptoms (DRESS). If a serious hypersensitivity reaction is suspected, perampanel should be discontinued immediately and appropriate medical care initiated; re-challenge should be avoided.
Perampanel has not been studied in patients with severe hepatic impairment (Child-Pugh class C), severe renal impairment, or those undergoing haemodialysis, and its use in these populations is not recommended. Patients with moderate hepatic impairment (Child-Pugh class B) or moderate renal impairment require dose adjustment and increased clinical caution.
Warnings and Precautions
Serious psychiatric and behavioural reactions: Clinical trials and post-marketing surveillance have identified dose-related psychiatric adverse events as a particular concern with perampanel. Reported reactions include aggression, hostility, anger, irritability, anxiety, paranoia, confusion, and more rarely homicidal ideation and threats. These effects are generally more likely at doses of 8–12 mg daily and with rapid dose escalation. Patients, their families, and caregivers should be informed of the risk and advised to contact the prescribing clinician promptly if such changes occur. In most cases, adverse behavioural reactions respond to dose reduction or discontinuation.
Suicidal ideation and behaviour: Like all antiepileptic drugs as a class, perampanel is associated with a small increased risk of suicidal thoughts or behaviour. Pooled analyses of randomised trials with various AEDs have suggested an approximately twofold increase in suicidality compared with placebo. Patients, carers, and families should watch for emerging or worsening depression, unusual mood changes, or suicidal thoughts, and seek medical advice without delay if such symptoms occur. This small risk must be weighed against the established morbidity and mortality of untreated seizures, which are substantially greater.
Dizziness, somnolence, and risk of falls: Dizziness and somnolence are the most commonly reported adverse events in clinical trials, each affecting more than one in five patients at therapeutic doses. These central nervous system effects are dose-related and most pronounced during initiation and dose escalation, often improving with continued therapy or slower titration. Dizziness and impaired coordination can increase the risk of falls, especially in elderly patients and those with pre-existing gait or balance disorders. Patients should be warned not to drive or operate heavy machinery until they know how perampanel affects them.
Interaction with alcohol: A dedicated interaction study demonstrated that perampanel combined with alcohol significantly worsens driving-related performance, increases feelings of anger, confusion, and depression, and impairs alertness more than alcohol alone. Patients should be strongly advised to avoid or strictly limit alcohol during treatment with perampanel.
Withdrawal of treatment: As with all antiepileptic drugs, abrupt discontinuation of perampanel can precipitate rebound seizures and, in extreme cases, status epilepticus. If discontinuation is clinically required, perampanel should be withdrawn gradually, typically over several weeks, unless safety concerns (such as severe hypersensitivity) necessitate more rapid withdrawal under close medical supervision.
Pre-existing psychiatric and substance use disorders: Given the potential for psychiatric adverse events, caution is warranted in patients with a history of psychiatric illness, aggression, or substance misuse. Such a history is not an absolute contraindication but should prompt more careful monitoring, slower titration, and a lower target dose when feasible. Perampanel is a controlled substance in several jurisdictions (including Schedule III under the U.S. Controlled Substances Act) owing to a measurable abuse potential at supratherapeutic doses.
Perampanel Vivanta should only be used under the supervision of a physician experienced in treating epilepsy. Any new or worsening psychiatric symptoms, suicidal thoughts, aggression, or severe mood changes should be reported to a healthcare professional without delay. Never stop perampanel abruptly without medical guidance, as this can provoke rebound seizures or status epilepticus.
Pregnancy and Breastfeeding
There are limited data on the use of perampanel in pregnant women. Animal reproductive studies have shown evidence of reproductive toxicity at clinically relevant exposures, including developmental delays and reduced offspring viability. Perampanel is not recommended during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the fetus. Women of childbearing potential who are not using effective contraception should not take perampanel. Where pregnancy occurs during perampanel therapy, the treatment should be re-evaluated promptly by a neurologist experienced in epilepsy in pregnancy, and enrolment in an international epilepsy pregnancy registry should be considered to help improve evidence for future patients.
Epilepsy in pregnancy requires a careful balance: uncontrolled tonic-clonic seizures pose meaningful risks to both mother and fetus, including trauma, hypoxia, and possible miscarriage. Abrupt discontinuation of antiepileptic therapy for fear of teratogenicity can therefore be harmful. Decisions about perampanel during pregnancy should be individualised and made together with the treating neurologist and, where available, a specialist in maternal-fetal medicine.
It is not known whether perampanel is excreted into human breast milk, but preclinical data suggest that it is excreted in the milk of lactating rats. Because of the potential for serious adverse reactions in breastfed infants, a decision should be made whether to discontinue breastfeeding or to discontinue perampanel, taking into account the importance of the medicine to the mother and the developmental and health benefits of breastfeeding to the infant.
Fertility studies with perampanel in animals have not indicated effects on fertility at clinically relevant doses. Human data on fertility are limited.
How Does Perampanel Vivanta Interact with Other Drugs?
Perampanel undergoes extensive hepatic metabolism, predominantly via oxidation by cytochrome P450 3A4 (CYP3A4) and, to a lesser extent, CYP3A5, followed by conjugation through glucuronidation. Because of this metabolic pathway, concomitant medications that strongly induce or inhibit CYP3A4 can meaningfully alter perampanel exposure. Conversely, perampanel itself can modestly affect the pharmacokinetics of several drugs, most notably levonorgestrel, via moderate induction of CYP3A4 at high doses.
Impact of enzyme-inducing antiepileptic drugs: Several commonly used antiepileptics are potent inducers of CYP3A4, and co-administration with perampanel can reduce perampanel plasma concentrations by 50% or more. In particular, carbamazepine reduces perampanel AUC by approximately 67%, oxcarbazepine by approximately 50%, and phenytoin by approximately 50%. When perampanel is used with these agents, a higher maintenance dose is often required, and the target dose may need to be reached through continued upward titration. If an enzyme-inducing AED is added to, changed, or withdrawn from an existing perampanel regimen, close clinical monitoring and dose re-evaluation are essential because perampanel levels may change markedly over the following days to weeks.
Impact of strong CYP3A4 inhibitors: Strong CYP3A4 inhibitors, including ketoconazole, itraconazole, clarithromycin, and HIV protease inhibitors such as ritonavir, can raise perampanel plasma concentrations. Although no routine dose adjustment is recommended, enhanced monitoring for dose-related adverse effects (dizziness, somnolence, mood changes) is advisable when such combinations cannot be avoided.
Hormonal contraception: Perampanel 12 mg once daily reduces plasma levels of levonorgestrel by approximately 40%, with a smaller reduction in ethinylestradiol. At 8 mg daily, no clinically significant reduction was observed. Consequently, women of childbearing potential taking 12 mg perampanel and using hormonal contraception containing levonorgestrel (including many combined oral contraceptives and progestogen-only pills, as well as levonorgestrel-only emergency contraception) should use an additional non-hormonal method, such as a barrier method or an intrauterine device, to ensure reliable contraception.
Major Interactions
| Drug / Substance | Effect | Recommendation |
|---|---|---|
| Carbamazepine | Reduces perampanel AUC by ~67% | Higher perampanel maintenance dose often required; monitor seizure control when starting or stopping |
| Phenytoin | Reduces perampanel AUC by ~50% | Consider higher perampanel dose; re-evaluate on any regimen change |
| Oxcarbazepine / eslicarbazepine | Reduces perampanel AUC by ~50% | Higher perampanel dose may be needed; monitor response |
| Ketoconazole, itraconazole, ritonavir (strong CYP3A4 inhibitors) | Increases perampanel plasma levels | Monitor for dose-related CNS and psychiatric adverse effects; avoid if possible |
| Levonorgestrel-containing contraceptives | Perampanel 12 mg reduces levonorgestrel AUC by ~40% | Use an additional non-hormonal method of contraception at the 12 mg dose |
| Alcohol (ethanol) | Markedly increases impairment of alertness, driving, and mood | Avoid or strictly limit alcohol during treatment |
| Benzodiazepines, opioids, other CNS depressants | Additive sedation, cognitive and motor impairment | Use with caution; avoid activities requiring alertness |
Minor Interactions
Perampanel does not appear to meaningfully affect the plasma concentrations of most other antiepileptic drugs commonly used in combination therapy. In population pharmacokinetic analyses from the pivotal trials, perampanel did not produce clinically significant changes in plasma levels of carbamazepine, clobazam, clonazepam, lamotrigine, levetiracetam, phenobarbital, phenytoin, topiramate, valproic acid, or zonisamide. This relative metabolic inertness towards other AEDs simplifies its use as adjunctive therapy in polypharmacy regimens.
Perampanel has been evaluated for possible interactions with midazolam (a sensitive CYP3A4 substrate used as a probe drug) and showed only a small, clinically insignificant effect. Nevertheless, when perampanel is used at higher doses alongside drugs with narrow therapeutic indices that are predominantly metabolised by CYP3A4, enhanced clinical monitoring is prudent.
No clinically significant interaction has been observed between perampanel and digoxin or warfarin. Food does not affect the extent of perampanel absorption but can delay its rate of absorption, with a modest reduction in peak concentration (Cmax) and a slight delay in Tmax when taken with a high-fat meal.
Before starting Perampanel Vivanta, give your prescribing doctor a complete list of all medicines you take, including prescription drugs, over-the-counter products, herbal remedies (particularly St John's wort, which is a strong CYP3A4 inducer), and recreational substances. Always inform other prescribers that you are taking perampanel before any new medicine is started.
What Is the Correct Dosage of Perampanel Vivanta?
Perampanel dosing should be individualised based on patient age, weight, concomitant antiepileptic therapy, hepatic and renal function, and clinical response. The goal is to achieve a therapeutic effect at the lowest effective dose, minimising dose-dependent neurological and psychiatric adverse effects. Because of perampanel's long half-life (approximately 105 hours), steady-state plasma concentrations are only reached after about 2–3 weeks at a constant dose, which is why dose increases should generally not be made more often than every 1–2 weeks.
Adults
Focal-Onset Seizures (Adults and Adolescents ≥ 12 years)
The recommended starting dose is 2 mg once daily at bedtime. The dose may be increased in 2 mg increments, no more frequently than every 2 weeks (or every week if perampanel is given with a CYP3A4-inducing AED such as carbamazepine or phenytoin), based on clinical response and tolerability. The usual maintenance dose range is 4–8 mg once daily, with a maximum approved dose of 12 mg once daily. Some patients derive additional benefit at 8–12 mg, but higher doses also carry a higher risk of adverse effects, including psychiatric events.
Primary Generalised Tonic-Clonic Seizures (Adults and Adolescents ≥ 12 years)
The recommended starting dose is 2 mg once daily at bedtime, titrated upwards in 2 mg steps no more often than every 2 weeks according to response and tolerability. The typical target dose is 8 mg once daily, although some patients respond at lower doses (e.g. 4–6 mg) and others may require the maximum approved dose of 12 mg once daily. Dose escalation beyond 8 mg should be undertaken cautiously in view of increased adverse-event burden.
Patients Receiving Enzyme-Inducing Antiepileptic Drugs
When perampanel is co-administered with strong inducers of CYP3A4 such as carbamazepine, phenytoin, or oxcarbazepine, perampanel plasma levels are substantially reduced. In these patients, a faster titration schedule (increments every week rather than every 2 weeks) and a higher final dose may be required to achieve therapeutic plasma concentrations. Conversely, if an enzyme-inducing AED is discontinued while perampanel is continued, perampanel levels will rise and a dose reduction may be necessary.
Children
Perampanel is approved for use in paediatric patients aged 4 years and older for focal-onset seizures and 7 years and older for primary generalised tonic-clonic seizures. In children weighing 30 kg or more, dosing is generally the same as in adolescents and adults: start at 2 mg once daily at bedtime, titrate in 2 mg steps every 1–2 weeks, to a maintenance dose of 4–8 mg (with a maximum of 12 mg). For children weighing less than 30 kg, a weight-based schedule is used with smaller dose increments.
| Body Weight | Starting Dose | Titration Step | Typical Maintenance |
|---|---|---|---|
| < 20 kg | 1 mg once daily | +1 mg every 1–2 weeks | 4–6 mg once daily |
| 20–< 30 kg | 1 mg once daily | +1 mg every 1–2 weeks | 4–8 mg once daily |
| ≥ 30 kg | 2 mg once daily | +2 mg every 1–2 weeks | 4–8 mg once daily (max 12 mg) |
The 2 mg film-coated tablet of Perampanel Vivanta is not ideal for patients requiring 1 mg doses. For young paediatric patients under 30 kg, an oral suspension formulation of perampanel is available from the originator manufacturer and should be used where accurate 1 mg increments are needed.
Elderly
Population pharmacokinetic analyses suggest no clinically meaningful differences in perampanel exposure between older and younger adults. However, elderly patients are more likely to have concomitant medical conditions, take multiple medications, and be vulnerable to adverse effects such as falls due to dizziness or somnolence. Therefore, slower dose titration (every 2 weeks) and a lower target maintenance dose are prudent in this population. Close monitoring for adverse effects, cognitive impairment, and interactions with commonly used cardiovascular and psychotropic medications is recommended.
Patients with Hepatic or Renal Impairment
In patients with mild hepatic impairment (Child-Pugh class A), no dose adjustment is required, but slower titration (no more frequently than every 2 weeks) is recommended. In moderate hepatic impairment (Child-Pugh class B), the initial dose should remain 2 mg, and the maximum dose should not exceed 6 mg once daily. Perampanel has not been studied in severe hepatic impairment and should not be used.
In patients with mild to moderate renal impairment, no dose adjustment is needed, although slower titration and careful monitoring are advisable. Perampanel is not recommended in patients with severe renal impairment or those undergoing haemodialysis, as these populations have not been adequately studied.
Missed Dose
If you miss a single dose of Perampanel Vivanta, take it as soon as you remember on the same day, unless it is close to the time of your next dose. If it is almost time for your next dose, skip the missed dose and resume your regular once-daily schedule the following evening. Do not take two doses in one 24-hour period to make up for a missed dose, as this increases the risk of adverse effects without improving seizure control. If several consecutive doses are missed (more than a few days), contact your prescribing doctor for advice, as restarting may require a brief re-titration because of the potential for adverse effects when resuming at the previous dose.
Overdose
There is limited clinical experience with perampanel overdose. A case of intentional ingestion of up to 264 mg has been reported, resulting in altered mental status, agitation, and aggressive behaviour, which resolved without sequelae. Because of perampanel's long half-life, the clinical effects of an overdose may be prolonged, and patients may need observation for several days. There is no specific antidote. Management consists of supportive care, with attention to airway protection, cardiovascular monitoring, and treatment of agitation or psychiatric symptoms. Activated charcoal may be considered if presentation is early. Due to extensive plasma protein binding, haemodialysis is unlikely to remove significant amounts of perampanel.
If an overdose of Perampanel Vivanta is suspected, seek immediate medical attention or contact your local poison control centre. Bring the medication packaging to help clinicians identify the drug and dose involved. Do not attempt to drive to the hospital yourself if you feel drowsy or confused.
What Are the Side Effects of Perampanel Vivanta?
Like all medicines, Perampanel Vivanta can cause side effects, although not everyone who takes it will experience them. The following adverse reactions have been identified in the pivotal randomised trials and post-marketing surveillance. Frequencies follow the standard MedDRA convention: very common (affects more than 1 in 10 people), common (affects 1 in 10 to 1 in 100 people), uncommon (affects 1 in 100 to 1 in 1,000 people), and rare (affects fewer than 1 in 1,000 people).
A defining feature of perampanel's tolerability profile is the clear dose-dependence of many CNS adverse effects. At 4 mg daily the adverse-event profile is generally mild and often comparable to placebo for several symptoms, while at 12 mg the incidence of dizziness, somnolence, fatigue, and psychiatric reactions rises substantially. Slow titration and selection of the lowest effective dose are therefore important strategies to improve tolerability in routine clinical practice.
Very Common
Affects more than 1 in 10 people
- Dizziness (vertigo sensation, unsteadiness)
- Somnolence (drowsiness, daytime sleepiness)
Common
Affects 1 in 10 to 1 in 100 people
- Fatigue, tiredness
- Irritability, anger
- Aggression, hostility
- Anxiety
- Mood changes, depressed mood
- Headache
- Gait disturbance, coordination problems
- Falls (particularly in elderly)
- Blurred vision, diplopia (double vision)
- Vertigo
- Nausea
- Weight gain, increased appetite
- Decreased appetite
- Back pain
- Dysarthria (slurred speech)
- Confusional state
Uncommon
Affects 1 in 100 to 1 in 1,000 people
- Suicidal ideation, suicide attempt
- Psychotic disorder, paranoia
- Disorientation
- Agitation
- Hypersomnia
- Memory impairment
- Confusion worsening cognitive function
- Tremor
- Hyponatraemia
- Drug hypersensitivity, rash
Rare
Affects fewer than 1 in 1,000 people
- Homicidal ideation or threats
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
- Status epilepticus (particularly after abrupt withdrawal)
- Severe cutaneous hypersensitivity reactions
- Dependence and withdrawal syndrome (supratherapeutic use)
Psychiatric adverse events warrant specific attention. In controlled trials of adult focal-onset seizures, treatment-emergent psychiatric events were reported in approximately 18% of patients receiving perampanel 12 mg and 17% receiving 8 mg, compared with 11% receiving placebo. Aggression-related events were reported in approximately 12% of adolescents on 8–12 mg, compared with approximately 3% on placebo. Most of these events were mild to moderate and resolved with dose reduction or discontinuation, but serious and clinically significant events have occurred and require urgent clinical evaluation.
Weight gain during treatment has been observed, with approximately 10% of patients gaining at least 7% of their baseline body weight during long-term studies. The mechanism is not fully understood but may involve increased appetite and reduced physical activity during somnolence. Regular monitoring of weight and lifestyle advice are sensible additions to routine follow-up.
Cognitive and neuropsychological effects have been reported in a minority of patients, including impaired concentration, memory difficulties, and slowed mental processing. These effects are typically dose-related and often improve with dose reduction. Formal neuropsychological studies suggest that, compared with several older AEDs, perampanel has a relatively favourable cognitive profile at therapeutic doses, although individual variation is substantial.
Contact your doctor or seek urgent medical care if you experience: new or worsening thoughts of self-harm or suicide; sudden severe agitation, aggression, or disturbing changes in mood or personality; a seizure that is longer or more severe than usual, or a rapid increase in seizure frequency; signs of a severe allergic reaction such as facial swelling, widespread rash with fever, or difficulty breathing; or a fall causing injury. Do not stop Perampanel Vivanta abruptly, as this can provoke rebound seizures.
How Should You Store Perampanel Vivanta?
Perampanel Vivanta film-coated tablets should be stored at temperatures not exceeding 30°C (86°F). The tablets are best kept in their original blister packaging, which is designed to protect them from light, moisture, and accidental handling. Transferring tablets to a pill organiser is acceptable for short periods if needed for medication adherence, but long-term storage outside the original packaging may reduce product stability.
Keep Perampanel Vivanta out of the sight and reach of children. Because perampanel is a psychoactive, controlled medicine in several jurisdictions, additional precautions to prevent accidental or non-medical use are reasonable, such as storing the pack in a cabinet that can be closed or a secure medication box, particularly in households with adolescents.
Do not use Perampanel Vivanta after the expiry date stated on the carton and blister. The expiry date refers to the last day of the month indicated. Expired tablets may no longer provide reliable seizure protection and could theoretically contain degradation products. Do not dispose of unused or expired medication via wastewater or household waste. Return unused tablets to your pharmacy for safe disposal in accordance with local regulations on medicinal products. This protects both the environment and other people in the household.
Inspect the tablets before each dose. Perampanel Vivanta 2 mg tablets should be uniform in appearance. If you notice any discolouration, cracking, powdering, or unusual odour, do not take the tablet and consult your pharmacist for a replacement. Travel with perampanel in your hand luggage and consider carrying a copy of your prescription and a medical letter if travelling internationally, particularly to jurisdictions where perampanel is classified as a controlled substance.
What Does Perampanel Vivanta Contain?
Active ingredient: Each film-coated tablet contains 2 mg perampanel. Perampanel is an achiral small-molecule aryl pyridinone with high lipophilicity, which supports its rapid oral absorption and ability to cross the blood-brain barrier to reach its target in the central nervous system. The 2 mg strength is typically used for initiation of therapy and for small dose adjustments.
Inactive ingredients (excipients): The tablet core and film coating contain conventional pharmaceutical excipients that ensure mechanical integrity, consistent dissolution, and visual identification of the product. Typical excipients in perampanel film-coated tablets include:
- Tablet core: Lactose monohydrate (filler), low-substituted hydroxypropylcellulose (binder/disintegrant), povidone (binder), microcrystalline cellulose (filler), magnesium stearate (lubricant).
- Film coating: Hypromellose (film-forming polymer), talc (glidant), macrogol/polyethylene glycol (plasticiser), titanium dioxide (opacifier), and strength-specific colorants (such as iron oxides) used to distinguish different dosage strengths.
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take lactose-containing formulations of perampanel unless under strict medical supervision. If a patient has a history of any allergy or intolerance to pharmaceutical excipients, the prescribing physician or pharmacist should review the specific product insert for the locally dispensed Perampanel Vivanta formulation, as minor differences in excipients may exist between generic versions approved in different regulatory jurisdictions.
Generic formulations of perampanel, including Perampanel Vivanta, must demonstrate bioequivalence to the originator product (Fycompa) according to regulatory standards set by the EMA, FDA, and other national medicines authorities. Bioequivalence studies typically show that generic and originator formulations produce essentially the same plasma concentration-time profiles, supporting their clinical interchangeability in most patients.
Frequently Asked Questions About Perampanel Vivanta
Fycompa is the original brand-name product developed by Eisai and first approved in 2012, while Perampanel Vivanta is a generic version that became available after the expiry of market exclusivity. Both contain the same active ingredient, perampanel, and must demonstrate bioequivalence to the originator product according to strict regulatory standards. In clinical practice, generic and branded versions are expected to produce essentially the same therapeutic effect. The main practical differences are pricing, tablet appearance, and the specific list of excipients used in the film coating and tablet core.
Perampanel is taken once daily at bedtime for two complementary reasons. First, the most common side effects are dizziness and somnolence, so taking the dose at night allows much of the peak drug concentration to coincide with sleep, reducing the impact of these effects on daytime activities such as driving and work. Second, evening dosing corresponds to natural circadian patterns of seizure susceptibility in many patients. Because of perampanel's long half-life (around 105 hours), missing the exact timing by an hour or two does not substantially affect steady-state levels, but taking it in the morning would make daytime sedation more likely.
Some patients notice a reduction in seizure frequency within a few weeks of reaching a therapeutic maintenance dose (typically 4–8 mg daily), but because perampanel has a long half-life, steady-state plasma levels are only reached about 2–3 weeks after each dose change. For this reason, the full effect of a given dose is usually assessed after at least one month of stable therapy. In clinical trials, differences between perampanel and placebo became statistically significant during the maintenance phase after gradual titration. A fair evaluation of efficacy therefore requires patience, slow titration, and consistent daily dosing, ideally tracked in a seizure diary.
Yes. Perampanel is approved as adjunctive therapy for focal-onset seizures in children from 4 years of age and for primary generalised tonic-clonic seizures in children from 7 years of age. Dosing is based on body weight: children weighing 30 kg or more generally follow the adult schedule, while those below 30 kg receive a weight-adjusted regimen that may require the oral suspension formulation from the originator manufacturer to deliver accurate 1 mg increments. Children must be followed carefully for behavioural and cognitive changes, which can sometimes present differently from those in adults, and dose adjustments should be guided by a paediatric neurologist or epileptologist.
Perampanel commonly causes dizziness and somnolence, and can produce slowed reaction times and, at higher doses, impaired judgement. These effects are particularly prominent during initiation and after dose escalation. Until you and your doctor are confident about how perampanel affects you, you should not drive or operate heavy machinery. Even once a stable dose is established, you should avoid driving if you feel drowsy, dizzy, or confused. National driving regulations for people with epilepsy also apply and generally require a minimum seizure-free interval before driving can be resumed. Combining perampanel with alcohol makes driving impairment significantly worse and should be avoided.
If you, your family, or caregivers notice new or worsening aggression, hostility, anger, anxiety, depressed mood, or thoughts of harming yourself or others while taking Perampanel Vivanta, contact your prescribing doctor promptly. Do not stop the medication abruptly on your own, as this can trigger rebound seizures. Your doctor may reduce the dose, slow further titration, or switch you to an alternative antiepileptic drug, depending on severity. In an acute crisis, such as severe aggression or suicidal thoughts, seek emergency medical care. Informing your household and carers in advance about these possible effects helps ensure early recognition and timely intervention.
Only under medical supervision. Decisions to reduce or discontinue any antiepileptic drug, including perampanel, must be individualised and weighed carefully against the risk of seizure recurrence. Sustained seizure freedom for at least 2–5 years is usually a prerequisite for considering withdrawal, alongside other factors such as seizure type, EEG findings, MRI abnormalities, and patient preference. Perampanel should always be tapered gradually, typically over several weeks or longer, to minimise the risk of rebound seizures and, in rare cases, status epilepticus. Never stop perampanel abruptly or adjust the dose yourself without first discussing it with your neurologist.
References
- European Medicines Agency (EMA). Fycompa (perampanel) Summary of Product Characteristics. Last updated 2025. Available at: EMA – Fycompa.
- U.S. Food and Drug Administration (FDA). Fycompa (perampanel) Prescribing Information. Revised 2024. Available at: FDA – Fycompa Label.
- French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589-596. doi:10.1212/WNL.0b013e3182635735.
- Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408-1415. doi:10.1212/WNL.0b013e318254473a.
- French JA, Krauss GL, Wechsler RT, et al. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial. Neurology. 2015;85(11):950-957. doi:10.1212/WNL.0000000000001930.
- Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54(8):1481-1489. doi:10.1111/epi.12212.
- National Institute for Health and Care Excellence (NICE). Epilepsies in children, young people and adults (NG217). 2022. London: NICE.
- Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I. Neurology. 2018;91(2):74-81.
- Lagae L, Villanueva V, Meador KJ, et al. Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: a randomized study evaluating behavior, efficacy, and safety. Epilepsia. 2016;57(7):1120-1129.
- World Health Organization (WHO). Epilepsy fact sheet. Updated 2024. Geneva: WHO.
- International League Against Epilepsy (ILAE). ILAE classification and definitions of epilepsy syndromes. Epilepsia. 2022;63(6):1333-1348.
- Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56(1):12-27. doi:10.1111/epi.12865.
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Neurology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel of medical experts
Evidence Level
Level 1A – Based on systematic reviews, meta-analyses, and randomized controlled trials
Guidelines
ILAE, NICE, EMA, FDA, and WHO international guidelines
All content is independently produced without commercial funding. Our editorial team follows the GRADE evidence framework and adheres to international guidelines from the International League Against Epilepsy (ILAE), the UK National Institute for Health and Care Excellence (NICE), the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and the World Health Organization (WHO). Content is reviewed and updated regularly to reflect the latest medical evidence.